
Royalty Pharma plc Class A Ordinary Shares
RPRX
RPRX: Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
moreShow RPRX Financials
Recent trades of RPRX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by RPRX's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Followers on RPRX's company Twitter account
Number of mentions of RPRX in WallStreetBets Daily Discussion
Recent insights relating to RPRX
Recent picks made for RPRX stock on CNBC
ETFs with the largest estimated holdings in RPRX
Flights by private jets registered to RPRX